09.29.26 -- Why You Should Measure Comparability Debt Before Ever Starting A Study

Learn how combining polymorph screening with structural informatics improves solid‑form selection, lowers development risk, and boosts confidence in long‑term stability and manufacturability.

Rapid analytical testing turnaround is essential to maintaining development timelines, meeting clinical milestones, and in commercial manufacturing, providing reliable drug supply to patients.

Common GMP pitfalls stem from poor scalability, late regulatory planning, weak tech transfer, unsuitable hosts, and inadequate quality systems, delaying biologics production timelines and budgets.

Scaling mammalian biologics relies on mirrored infrastructure and single-use technologies to streamline tech transfer and enable cost-efficient commercialization.

Explore how an innovative platform, powered by Selexis®, accelerates the development of complex biologics from early stages to first-in-human (FIH) trials, focusing on both speed and quality.

Patient centricity is reshaping pharma drug development through supply chain resiliency, decentralized trials, and patient-friendly formulations. See what these shifts mean for your pipeline strategy.

Observe how streamlined, scalable platforms are transforming viral vector manufacturing to accelerate the delivery of cell and gene therapies to patients.

Leverage advanced elemental impurity testing methods to ensure the safety, compliance, and accuracy of your drug products throughout the manufacturing process.

As CDMO networks expand, disconnected quality processes create delays and risk. Find out how seamless external collaboration improves visibility, accelerates approvals, and strengthens relationships.